Increasing psychotherapy dose from 8 to 16 sessions does not improve social functioning in people with major depressive disorder receiving pharmacotherapy

2012 ◽  
Vol 15 (2) ◽  
pp. 50-50
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Social Functioning ◽  
Major Depressive

Anhedonia predicts poor psychosocial functioning: Results from a large cohort of patients treated for major depressive disorder by general practitioners

2017 ◽  
Vol 44 ◽  
pp. 1-8 ◽  
Author(s):  
F. Vinckier ◽  
D. Gourion ◽  
S. Mouchabac
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Social Functioning ◽  
Psychosocial Functioning ◽  
Multivariate Regression ◽  
Antidepressant Treatment ◽  
Major Depressive ◽  
Pharmacological Management ◽  
Mediation Analyses ◽  
Symptomatic Remission

AbstractBackground:Anhedonia is a core symptom of major depression and a key prognostic factor that is often poorly explored in clinical trials of major depressive disorder (MDD). Beyond symptomatic remission, psychosocial functioning also reveals difficulty in achieving remission in patients with MDD. The main objective of this study was to explore the interrelationships between social functioning and anhedonia on a longitudinal basis.Methods:In total, 1570 outpatients treated for MDD with agomelatine were included. Severity of depression and levels of anhedonia and of psychosocial functioning were assessed at inclusion and at 10–14 weeks, with specific standardized scales (MADRS, QFS, SHAPS, CGI). Multivariate regression and mediation analyses were performed.Results:Using multivariate regression, we showed that improvement of anhedonia was the strongest predictor of improvement in psychosocial functioning (odds ratio = 7.3 [4.3–12.1] P < 0.0001). In addition, mediation tests confirmed that the association between improvement of depressive symptoms and improvement of social functioning was significantly underpinned by the improvement of anhedonia over time. Finally, we explored the determinants of the dissociation of the response, i.e., the persistence of psychosocial dysfunctioning despite a symptomatic response to antidepressant treatment, which remains a widespread situation in clinical practice. We showed that this dissociation was strongly predicted by persistence of anhedonia.Conclusion:Our results suggest that anhedonia is one of the strongest predictors of psychosocial functioning, along with symptomatic remission, and should be carefully assessed by health professionals, in order to optimize pharmacological as well as non-pharmacological management of depression.

scholarly journals An Overview on Depression: An Approach to Disorder and Management

2021 ◽  
pp. 336-340
Author(s):  
Kartik Pandya ◽  
Chintan Aundhia ◽  
Avinash Seth ◽  
Nirmal Shah ◽  
Dipti Gohil ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Central Nervous System ◽  
Nervous System ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Social Functioning ◽  
Daily Activities ◽  
Major Depressive ◽  
Central Nervous System Disorders ◽  
The Brain

Central nervous system (CNS) disorder is the world’s leading cause of disability and account of more hospitalizations. Central nervous system disorders are a group of neurological disorder that affect the structure or function of the brain or spinal cord. Depression (major depressive disorder or clinical depression) is a common but serious mood disorder. It causes severe symptoms that affect how you feel, think, and handle daily activities, such as sleeping, eating, or working. The aim of treatment is release of neurotrophic proteins in the brain that can help to rebuild the hippocampus that has been reduced due to depression and to optimize patients’ physical, psychological and social functioning. This review presents a brief summary on psychological implications of living with depression, pathogenesis, diagnosis, causes, sign and symptoms and treatments associated with depression.

scholarly journals Social functioning in major depressive disorder

2016 ◽  
Vol 69 ◽  
pp. 313-332 ◽  
Author(s):  
Aleksandra Kupferberg ◽  
Lucy Bicks ◽  
Gregor Hasler
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Social Functioning ◽  
Major Depressive

scholarly journals Grip Strength, Neurocognition, and Social Functioning in People WithType-2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizophrenia

2020 ◽  
Vol 11 ◽  
Author(s):  
María Aliño-Dies ◽  
Joan Vicent Sánchez-Ortí ◽  
Patricia Correa-Ghisays ◽  
Vicent Balanzá-Martínez ◽  
Joan Vila-Francés ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bipolar Disorder ◽  
Type 2 Diabetes Mellitus ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Social Functioning ◽  
Cognitive Performance ◽  
Major Depressive

Background: Frailty is a common syndrome among older adults and patients with several comorbidities. Grip strength (GS) is a representative parameter of frailty because it is a valid indicator of current and long-term physical conditions in the general population and patients with severe mental illnesses (SMIs). Physical and cognitive capacities of people with SMIs are usually impaired; however, their relationship with frailty or social functioning have not been studied to date. The current study aimed to determine if GS is a valid predictor of changes in cognitive performance and social functioning in patients with type-2 diabetes mellitus and SMIs. Methods: Assessments of social functioning, cognitive performance, and GS (measured with an electronic dynamometer) were conducted in 30 outpatients with type 2 diabetes mellitus, 35 with major depressive disorder, 42 with bipolar disorder, 30 with schizophrenia, and 28 healthy controls, twice during 1-year, follow-up period. Descriptive analyses were conducted using a one-way analysis of variance for continuous variables and the chi-squared test for categorical variables. Differences between groups for the motor, cognitive, and social variables at T1 and T2 were assessed using a one-way analysis of covariance, with sex and age as co-variates (p &lt; 0.01). To test the predictive capacity of GS at baseline to explain the variance in cognitive performance and social functioning at T2, a linear regression analysis was performed (p &lt; 0.05). Results: Predictive relationships were found among GS when implicated with clinical, cognitive, and social variables. These relationships explained changes in cognitive performance after one year of follow-up; the variability percentage was 67.7%, in patients with type-2 diabetes mellitus and 89.1% in patients with schizophrenia. Baseline GS along with other variables, also predicted changes in social functioning in major depressive disorder, bipolar disorder, and schizophrenia, with variability percentages of 67.3, 36, and 59%, respectively. Conclusion: GS combined with other variables significantly predicted changes in cognitive performance and social functioning in people with SMIs or type-2 diabetes mellitus. Interventions aimed to improve the overall physical conditions of patients who have poor GS could be a therapeutic option that confers positive effects on cognitive performance and social functioning.

scholarly journals Transdiagnostic neurocognitive deficits in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: A 1-year follow-up study

2021 ◽  
Author(s):  
Patricia Correa-Ghisays ◽  
Joan Vicent Sánchez-Ortí ◽  
Vicent Balanzá-Martínez ◽  
Gabriel Selva-Vera ◽  
Joan Vila-Francés ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Bipolar Disorder ◽  
Type 2 Diabetes Mellitus ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Social Functioning ◽  
Major Depressive

AbstractBackgroundImpairments in neurocognition are critical factors in patients with major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SZ), and also in those with somatic diseases such as type 2 diabetes mellitus (T2DM). Intriguingly, these severe mental illnesses are associated with an increased co-occurrence of diabetes (direct comorbidity). This study sought to investigate the neurocognition and social functioning across T2DM, MDD, BD, and SZ using a transdiagnostic and longitudinal approach.MethodsA total of 165 subjects, including 30 with SZ, 42 with BD, 35 with MDD, 30 with T2DM, and 28 healthy controls (HC), were assessed twice at a 1-year interval using a comprehensive, integrated test battery on neuropsychological and social functioning.ResultsCommon neurocognitive impairments in somatic and psychiatric disorders were identified, including deficits in short-term memory and cognitive reserve (p < 0.01; η2p = 0.08-0.31). Social functioning impairments were observed in almost all the disorders (p < 0.0001; η2p = 0.29-0.49). Transdiagnostic deficits remained stable across the 1-year follow-up (p < 0.001; η2p = 0.13-0.43) and could accurately differentiate individuals with somatic and psychiatric disorders (χ2 = 48.0, p < 0.0001).ConclusionsThis longitudinal study provides evidence of the overlap in neurocognition deficits across somatic and psychiatric diagnostic categories, such as T2DM, MDD, BD, and SZ, which have high comorbidity. This overlap may be a result of shared genetic and environmental etiological factors. The findings further lay forth promising avenues for research on transdiagnostic phenotypes of neurocognition in these disorders, in addition to their biological bases.

Sign in / Sign up

Export Citation Format

Share Document